Glenmark Pharmaceuticals has received final approval from USFDA for its generic version of AstraZeneca’s Xylocaine ointment. The approval is for Lidocaine Ointment USP, 5 per cent. Currently, the ointment has achieved annual sales of approximately USD 373.0 million. Glenmark’s current portfolio consists of 109 products authorised for distribution in the US and 62 ANDA’s pending approval with the US FDA.
Company Profile : Glenmark Pharma Ltd
Leave a Reply